Rheumatology
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
ACR Guidelines for the Treatment of Juvenile Idiopathic Arthritis.
4 Mar, 2022 | 08:58h | UTC
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.
3 Mar, 2022 | 08:46h | UTC
Commentary on Twitter
Our latest #Review is online now. #COVID-19 risks, outcomes and treatment considerations in #rheumatic disease.
Read it for #free here: https://t.co/WsmuyoFNGT@philipcrobinson pic.twitter.com/I4RWh0Gftr
— NatRevRheumatol (@NatRevRheumatol) February 28, 2022
Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the Global Burden of Disease Study 2019.
3 Mar, 2022 | 08:27h | UTCNews Release: Study reveals a persistently high burden of osteoarthritis across the globe – Wiley
A low-energy diet shows promise for reducing the symptoms of fibromyalgia.
3 Mar, 2022 | 08:23h | UTCEarly Relationships of a Low-Energy Diet With Symptoms of Fibromyalgia ACR Open Rheumatology
Commentary: Fibromyalgia Patients See Rapid Benefit From Low-Cal Diet — With marked symptom reduction in just 3 weeks, weight loss not a factor – MedPage Today (free registration required)
Erosive hand osteoarthritis: latest findings and outlook.
3 Mar, 2022 | 08:01h | UTCErosive hand osteoarthritis: latest findings and outlook – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Commentary on Twitter
#MarchIssue | Read our #Review on the clinical features and risk factors of erosive hand #osteoarthritis (an aggressive condition with poor outcomes), and progress in biomarkers, imaging, classification and treatmenthttps://t.co/GSvgnXYYPS pic.twitter.com/PSzeucO0cH
— NatRevRheumatol (@NatRevRheumatol) February 28, 2022
Guideline: Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis.
27 Feb, 2022 | 22:40h | UTC
Commentary on Twitter
New rapid recommendation makes a weak recommendation against plasma exchange in patients with low risk of end stage kidney disease, and a weak recommendation in favour of plasma exchange in patients with moderate-high risk of ESKD https://t.co/PeEjSuRIxI #BMJInfographic pic.twitter.com/YR55t6XYhS
— The BMJ (@bmj_latest) February 25, 2022
M-A: Fetal and maternal outcomes after maternal biologic use during conception and pregnancy.
25 Feb, 2022 | 10:43h | UTC
Anti-inflammatory treatment of Kawasaki Disease: comparison of current guidelines and perspectives.
25 Feb, 2022 | 10:29h | UTC
RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.
24 Feb, 2022 | 10:20h | UTCCommentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)
New practical aspects of Sweet Syndrome.
23 Feb, 2022 | 09:56h | UTCNew Practical Aspects of Sweet Syndrome – American Journal of Clinical Dermatology
Cohort Study: Osteoporosis and its association with cardiovascular disease, respiratory disease, and cancer.
18 Feb, 2022 | 08:24h | UTCOsteoporosis and Its Association With Cardiovascular Disease, Respiratory Disease, and Cancer: Findings From the UK Biobank Prospective Cohort Study – Mayo Clinic Proceedings (link to abstract – $ for full-text)
Dupuytren’s Disease—etiology and treatment.
17 Feb, 2022 | 08:25h | UTCDupuytren’s Disease—Etiology and Treatment – Deutsches Ärzteblatt International
Cohort Study: Depressed symptomatology persists over time in systemic lupus erythematosus patients.
17 Feb, 2022 | 08:15h | UTCCommentary: Depression persists in most lupus patients despite therapies, changes in disease activity – Healio (free registration required)
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
16 Feb, 2022 | 10:13h | UTC
Commentary on Twitter
A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig
— Eric Topol (@EricTopol) February 15, 2022
Systematic Review: Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations.
9 Feb, 2022 | 10:02h | UTC
New developments in systemic lupus erythematosus.
8 Feb, 2022 | 08:27h | UTCNew developments in systemic lupus erythematosus – Rheumatology
Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
8 Feb, 2022 | 08:24h | UTC
New developments in osteoarthritis pharmacological therapies.
8 Feb, 2022 | 08:25h | UTCNew developments in osteoarthritis pharmacological therapies – Rheumatology
New developments in ankylosing spondylitis.
8 Feb, 2022 | 08:26h | UTCNew developments in ankylosing spondylitis—status in 2021 – Rheumatology
New developments in Sjogren’s syndrome.
8 Feb, 2022 | 08:23h | UTCNew developments in Sjogren’s syndrome – Rheumatology
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
7 Feb, 2022 | 08:43h | UTC
2022 ACR/EULAR classification criteria for microscopic polyangiitis.
4 Feb, 2022 | 09:54h | UTC2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary on Twitter
🚨 # 2022 ACR/EULAR classification criteria for Rheumatology classification criteria for microscopic polyangiitis
1️⃣sensitivity 91%
2️⃣specificity 94%https://t.co/6pPHL8JGVH pic.twitter.com/NJdrS9c6gs— Annals of the Rheumatic Diseases (@eular_ARD) February 2, 2022
2022 ACR/EULAR Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
4 Feb, 2022 | 08:57h | UTC2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary on Twitter
🚨 # 2022 ACR/EULAR classification criteria for Eosinophilic Granulomatosis with Polyangiitis
1️⃣ sensitivity 85%
2️⃣ specificity 99%https://t.co/WWNk6n8Q09 pic.twitter.com/y41VnP39P7— Annals of the Rheumatic Diseases (@eular_ARD) February 2, 2022
2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis.
4 Feb, 2022 | 09:00h | UTC2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary on Twitter
🚨 # 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis
1️⃣sensitivity 93%
2️⃣specificity 94%https://t.co/pJzZydezBB pic.twitter.com/2PafF2pbzo— Annals of the Rheumatic Diseases (@eular_ARD) February 2, 2022